# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 14, 2023

## BIOATLA, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-39787 (Commission File Number) 85-1922320 (IRS Employer Identification No.)

11085 Torreyana Road San Diego, California (Address of Principal Executive Offices)

92121

(Zip Code)

Registrant's Telephone Number, Including Area Code: 858 558-0708

|  | (Former Name or Former Address, if Changed Since Last Report)   |           |  |  |  |
|--|---|-----------|--|--|--|
|  | Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |           |  |  |  |
|  | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   |           |  |  |  |
|  | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  |           |  |  |  |
|  | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  |           |  |  |  |
|  | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  |           |  |  |  |
|  | Securities registered pursuant to Section 12(b) of the Act:   |           |  |  |  |
|  |   | Trading   |  |  |  |
|  | Title of each class   | Symbol(s) | Name of each exchange on which registered                              |  |  |
| Common Stock, \$0.0001 par value per share |   | BCAB      | Nasdaq Global Market   |  |  |
|  | icate by check mark whether the registrant is an emergir<br>pter) or Rule 12b-2 of the Securities Exchange Act of 19  |           | ed in Rule 405 of the Securities Act of 1933 (§ 230.405 of this pter). |  |  |
| Em   | erging growth company $\square$   |           |  |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new

or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

#### Item 5.07 Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders of BioAtla, Inc. (the "*Company*") was held online via live audio webcast on June 14, 2023 (the "*Annual Meeting*"). At the Annual Meeting, there were present, in person virtually or by proxy, holders of 37,304,412 shares of common stock, or approximately 78.31% of the total outstanding shares eligible to be voted. The final voting results with respect to each proposal presented at the Annual Meeting is set forth below:

#### **Proposal One - Election of Directors**

The Company's stockholders approved the election of three Class III directors to the Company's Board of Directors for three year terms or until their respective successors are duly elected and qualified or until their earlier death, resignation, disqualification or removal, by the following votes:

| Nominee             | <b>Votes For</b> | Votes Withheld | <b>Broker Non-Votes</b> |
|---------------------|------------------|----------------|-------------------------|
| Jay M. Short, Ph.D. | 22,948,319       | 5,926,074      | 8,430,019               |
| Scott Smith         | 22,232,673       | 6,641,720      | 8,430,019               |
| Edward Williams     | 22,947,509       | 5,926,884      | 8,430,019               |

#### Proposal Two - Ratification of Appointment of Independent Registered Public Accounting Firm

The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 by the following votes:

| Votes For  | Votes Against | Abstentions |
|------------|---------------|-------------|
| 36,580,145 | 564,952       | 159,315     |

#### Proposal Three - Non-Binding Advisory Vote on the Executive Compensation of Our Named Executive Officers

The Company's stockholders approved, on a non-binding advisory basis, the executive compensation of our named executive officers by the following votes:

| Votes For  | Votes Against | Abstentions | <b>Broker Non-Votes</b> |
|------------|---------------|-------------|-------------------------|
| 27,451,774 | 1,375,886     | 46,733      | 8,430,019               |

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|       |               |     | BioAua, Inc.                                  |  |
|-------|---------------|-----|---|--|
| Date: | June 14, 2023 | By: | /s/ Richard A. Waldron                        |  |
|       |               |     | Richard A. Waldron<br>Chief Financial Officer |  |
|       |               |     |   |  |